Almac: more US connections
January 28, 2008
Following the Almac Group’s recent announcement of its $100m investment in its new North American headquarters, the company will be hosting a press gathering at their Northern Ireland headquarters. As well as further news of the expansion in the US, each of the group’s five divisions, including Almac Sciences, will provide updates on their latest product and service developments.
Shortly after last October’s CPhI in Milan, Almac Group announced a US $100m investment to create its new North American headquarters facility in Lower Salford Township, southeast Pennsylvania. Opening in 2010, a new 240,000 sq. ft. office and production complex will replace current facilities in Audubon and Yardley, with almost 500 jobs transferring and up to 400 new positions being created in phases by 2013.
The facility is a clear demonstration of group’s commitment to the US pharma services marketplace after a decade of development and expansion, based in a number of facilities in Pennsylvania, North Carolina and California.
Almac Sciences is one of the group’s five integrated divisions. Together, they provide a broad range of services from R&D, translational genomic services, API manufacture, formulation development, clinical trial supply and technology (IVRS/EDC), to commercial-scale manufacture.
Almac Sciences’ main services include contract R&D, custom manufacturing and analytical services. The division operates in a number of niche areas and sees service connectivity as an increasingly important part of its business offering.
Almac Sciences’ niche specialisms include: potent manufacture at 100+ kg scale, cytotoxics at 10s kg scale, chiral products and technology, micronisation, custom synthesis of peptides including peptide cytotoxic conjugates – and cGMP and non-GMP 14C labelling of NCEs from small molecule chirals to long peptides.
Total supply chain
“We continue to meet our customers’ diverse and increasingly complex needs by combining Almac’s world class capabilities with complementary services of other leading industry players”,
says David Moody, VP Commercial Operations.
“That means a total supply chain approach to manufacturing, with high-flexibility from mgs. to tonnes, irrespective of complexity and regulatory status, and a very special approach to key customers and preferred supplier relationships,”
he added.
Almac Sciences’ “Supply Chain Solution” model offers many connections across a rich network of continually developing services, linking manufacturing chemistry, raw material management, tech transfer and supported manufacture to deliver “quality on time in full”.
As Business Development VP Dr. Rosaleen McGuckin defines it:
“The flexibility of Almac Group’s global manufacturing and service network underpins Sciences’
commitment to align production and services wherever and whenever the customer wishes.
“Our local Business Development Managers are chosen for their deep and wide technical knowledge, enabling them to identify and translate customer needs into solutions.”
In a recent example of its technology transfer and low cost manufacturing alliance model, Almac Sciences developed a process for the synthesis of a complex chiral molecule in the UK, prior to technology transfer to India for closely supported, low-cost manufacture.
Contact: Rosaleen McGuckin
T: + 44 (0)28 3833 2200
Share